GlassScriptPhysician profile
Sarah T Schell
NPI 1831685791
$1,744.28
in general payments reported to CMS, 2019-2025
15 companies · $882 in 2025
The $882 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $298 · 2022: $278 · 2023: $119 · 2024: $168 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $329.04 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $246.62 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $242.63 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $202.47 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $184.04 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $166.41 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $97.88 | 2021-2025 | Invega Sustenna, Invega |
| Supernus Pharmaceuticals, INC. | $69.17 | 2022-2025 | Qelbree, Qelbree |
| Indivior INC. | $41.98 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $41.40 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.66 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.86 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $20.32 | 2025 | Jornay Pm |
| Braeburn INC. | $18.16 | 2025 | Brixadi |
| Corium, LLC | $14.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Schell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.